SCYXSCYNEXIS, Inc.

$38M

Q1 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$1M+21.5% YoY

Gross Profit

$1M100.0% margin

Operating Income

-$10M-692.5% margin

Net Income

$411,00029.9% margin

EPS (Diluted)

$0.01

QoQ Revenue Growth

-76.3%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

$0

Stock-Based Comp.

$705,000

Balance Sheet

Total Assets

$118M

Total Liabilities

$44M

Stockholders' Equity

$74M

Cash & Equivalents

$36M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$1M	+21.5%
Gross Profit	$1M	$993,000	+38.3%
Operating Income	-$10M	-$11M	+11.0%
Net Income	$411,000	-$34M	+101.2%

Revenue Segments

License and Service

$1M100%

SCYX Q1 2024 Earnings — SCYNEXIS, Inc. Revenue & Financial Results | Market Cap Arena